Evaluation of a Hydroxyethylstarch Solution for Dimethyl Sulfoxide Removal from Mobilized Peripheral Blood using an Automated System
DOI:
https://doi.org/10.46765/2675-374X.2023v4n2p193Keywords:
criopreservation, DMSO, mobilized peripheral blood, SEPAX 2™Abstract
Background and objectives: This study evaluates the efficacy of synthetic colloid hydroxyethyl starch for use as a washing solution to remove DMSO from hematopoietic stem cells cryopreserved grafts in comparison to a crystalloid based solution.
Materials and methods: We evaluated samples of cryopreserved mobilized peripheral blood (MPB) from 6 (six) patients that had not been used for transplant. For comparison, we used two equal bags of the same collection procedure, allowing the analysis of two different solutions simultaneously. Washing solutions were used: a crystalloid solution (solution 1, sodium chloride 0.9%) and a colloidal solution (solution 2, hydroxyethyl starch 6%), both added with human albumin 2.5%. The washes were performed using the SEPAX2™ (Biosafe) system automated methodology, using the CS-600.1 kit (Biosafe), according to the washing protocol established by the manufacturer.
Results: The washing solution containing HES showed a statistically significant increase in the recovery of CNT and CD34+/CD45+ cells (p = 0.0313, both), in addition to a greater number of CFU-GM colonies (without statistical significance) when compared to the 0.9% sodium chloride solution. Furthermore, the wash solution containing HES also prevented significant clumping, contrary to what was observed in the wash with 0.9% sodium chloride solution.
Conclusion: This work shows that the colloidal washing solution containing hydroxyethyl starch is a good option for DMSO removal procedures in samples of cryopreserved mobilized peripheral blood, maintaining the CD34+ cells viability and functionality and reducing the cell clumping.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 JOURNAL OF BONE MARROW TRANSPLANTATION AND CELLULAR THERAPY
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
License and Copyright Policy
The Journal of Bone Marrow Transplantation and Cellular Therapy (JBMTCT) adopts an open access policy, ensuring that all published articles are freely available to the public without restrictions.
-
License
- All articles published in JBMTCT are licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0).
- This license permits anyone to:
- Share: Copy and redistribute the material in any medium or format.
- Adapt: Remix, transform, and build upon the material for any purpose, even commercially.
- The only requirement is that appropriate credit is given to the original authors and source, a link to the license is provided, and any changes made are indicated.
More information about the license can be found here: Creative Commons Attribution 4.0 International License.
-
Authors’ Rights
- Authors retain the copyright to their work.
- Authors grant JBMTCT the right to publish the work and make it openly accessible online.
- Authors are free to:
- Distribute the published version of their article (e.g., post it on personal websites or institutional repositories).
- Use the article in future works, presentations, or derivative publications, as long as the original publication in JBMTCT is properly acknowledged.
-
No Embargo
- There is no embargo period; articles are made freely available immediately upon publication.
-
Ethical Use
- Users of JBMTCT articles must ensure proper citation of the authors and the journal.
- Articles must not be used in ways that violate ethical or legal standards.
-
Disclaimer
- While JBMTCT aims to ensure the accuracy and reliability of published content, the journal and its editors are not responsible for the consequences of its use.
For any questions regarding our licensing terms, please contact us at: journalbmtct@sbtmo.org.br
JBMTCT is committed to the principles of open access to advance knowledge and scientific collaboration.